Ratings for R1 RCM RCM were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 6 | 3 | 0 | 0 |
Last 30D | 2 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 4 | 3 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.92, a high estimate of $20.00, and a low estimate of $13.00. Observing a 8.52% increase, the current average has risen from the previous average price target of $14.67.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of R1 RCM among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Richard Close | Canaccord Genuity | Lowers | Buy | $16.00 | $17.00 |
Daniel Grosslight | Citigroup | Announces | Buy | $16.00 | - |
Sean Dodge | RBC Capital | Maintains | Outperform | $19.00 | - |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $20.00 | - |
Jailendra Singh | Truist Securities | Announces | Hold | $16.00 | - |
Daniel Grosslight | Citigroup | Raises | Buy | $16.00 | $14.00 |
Scott Schoenhaus | Keybanc | Raises | Overweight | $17.00 | $13.00 |
Stephanie Davis | Barclays | Maintains | Equal-Weight | $14.00 | $14.00 |
Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $16.00 | $12.00 |
Michael Cherny | Leerink Partners | Announces | Outperform | $14.00 | - |
Scott Schoenhaus | Keybanc | Lowers | Overweight | $13.00 | $18.00 |
Stephanie Davis | Barclays | Announces | Overweight | $14.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to R1 RCM. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of R1 RCM compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for R1 RCM's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of R1 RCM's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on R1 RCM analyst ratings.
All You Need to Know About R1 RCM
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received.
Understanding the Numbers: R1 RCM's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: R1 RCM's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 7.84%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: R1 RCM's net margin excels beyond industry benchmarks, reaching 0.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): R1 RCM's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): R1 RCM's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.63, R1 RCM adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.